Trimethoprim: Formulary list price $0.2617/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2617 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66985 · Verify on the e-Formulary ↗ (DIN 02243116)
Source record
DIN 02243116: Trimethoprim
Raw flags: sec3=Y
Item: 084000007; group id 140; item number 0235; lccId None; manufacturer id AAP
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.2617; ministry $0.2617
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243116
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66985Interchangeable products
Proloprim · DIN 00675229 · not recorded
Shortage status: resolved shortage (ended 2023-03-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243116
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Trimethoprim · DIN 02243117 · 200mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Trimethoprim · DIN 02243117
Manufacturer: A A Pharma Inc.; listing date 2001-06-07
Daily cost (source): $0.5378
Health Canada: Marketed since 2011-04-07 · brand TRIMETHOPRIM TABLETS · ATC J01EA01 TRIMETHOPRIM · form Tablet · route Oral · ingredients TRIMETHOPRIM 200 MG · company Aa pharma inc · schedule Prescription
Trimethoprim: Formulary list price $0.5378/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5378 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66986 · Verify on the e-Formulary ↗ (DIN 02243117)
Source record
DIN 02243117: Trimethoprim
Raw flags: sec3=Y
Item: 084000009; group id 140; item number 0236; lccId None; manufacturer id AAP
Source form: Tab; strength: 200mg
Recorded listing: General benefit
Source prices (unrounded): $0.5378; ministry $0.5378
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243117
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66986Interchangeable products
Proloprim · DIN 00677590 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243117
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Proloprim · DIN 00675229 · 100mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-10-28 — choose a marketed DIN from the same-category list.Discontinued 2003-10-28 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-10-28 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-10-28 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Proloprim · DIN 00675229
Manufacturer: Burroughs Wellcome Inc.; listing date 1996-10-01
Daily cost (source): $0.5234
Health Canada: Cancelled post market since 2003-10-28 · brand PROLOPRIM TAB 100MG · ATC J01EA01 TRIMETHOPRIM · form Tablet · route Oral · ingredients TRIMETHOPRIM 100 MG · company Glaxosmithkline inc · schedule Prescription
Proloprim: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6677 · Verify on the e-Formulary ↗ (DIN 00675229)
Source record
DIN 00675229: Proloprim
Raw flags: notABenefit=Y, sec3=Y
Item: 084000007; group id 140; item number 0235; lccId None; manufacturer id BWE
Source form: Tab; strength: 100mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00675229
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6677Interchangeable products
Trimethoprim · DIN 02243116 · $0.2617
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00675229
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2003-10-28 — choose a marketed DIN from the same-category list.
Proloprim · DIN 00677590 · 200mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2004-08-05 — choose a marketed DIN from the same-category list.Discontinued 2004-08-05 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2004-08-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2004-08-05 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Proloprim · DIN 00677590
Manufacturer: Burroughs Wellcome Inc.; listing date 1996-10-01
Daily cost (source): $0.5378
Health Canada: Cancelled post market since 2004-08-05 · brand PROLOPRIM 200 TAB 200MG · ATC J01EA01 TRIMETHOPRIM · form Tablet · route Oral · ingredients TRIMETHOPRIM 200 MG · company Glaxosmithkline inc · schedule Prescription
Proloprim: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6585 · Verify on the e-Formulary ↗ (DIN 00677590)
Source record
DIN 00677590: Proloprim
Raw flags: notABenefit=Y, sec3=Y
Item: 084000009; group id 140; item number 0236; lccId None; manufacturer id BWE
Source form: Tab; strength: 200mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00677590
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6585Interchangeable products
Trimethoprim · DIN 02243117 · $0.5378
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00677590
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2004-08-05 — choose a marketed DIN from the same-category list.
SULFAMETHOXAZOLE & TRIMETHOPRIM
Form:
9 of 9 products shown
3 general benefit · 6 not a benefit
Sulfatrim · DIN 00445274 · 400mg & 80mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Special Drugs ProgramSpecial Drugs Program: Amoxicillin, ascorbic acid (Vitamin C), deferoxamine, folic acid, hydrocortisone injection, penicillin and trimethoprim/sulfamethoxazole for the treatment of thalassaemia (ontario.ca, Updated 2023-07-13 ↗)
Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗)
The Special Drugs Program will cover costs for the above drugs if the patient:
is an Ontario resident
has a valid Ontario Health Insurance (OHIP)
has one of the diseases or conditions covered
meets the established clinical criteria
is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sulfatrim · DIN 00445274
Manufacturer: A A Pharma Inc.; listing date 1996-10-01
Daily cost (source): $0.8736
Health Canada: Marketed since 2019-06-07 · brand SULFATRIM · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Tablet · route Oral · ingredients TRIMETHOPRIM 80 MG, SULFAMETHOXAZOLE 400 MG · company Aa pharma inc · schedule Prescription
Sulfatrim: Formulary list price $0.2184/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2184 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3678 · Verify on the e-Formulary ↗ (DIN 00445274)
Source record
DIN 00445274: Sulfatrim
Raw flags: sec3=Y
Item: 084000001; group id 139; item number 0233; lccId None; manufacturer id AAP
Source form: Tab; strength: 400mg & 80mg
Recorded listing: General benefit
Source prices (unrounded): $0.2184; ministry $0.2184
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00445274
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3678Interchangeable products
Bactrim · DIN 00272469 · not recorded
Septra · DIN 00270636 · not recorded
Shortage status: resolved shortage (ended 2025-04-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00445274
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sulfatrim-DS · DIN 00445282 · 800mg & 160mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Special Drugs ProgramSpecial Drugs Program: Amoxicillin, ascorbic acid (Vitamin C), deferoxamine, folic acid, hydrocortisone injection, penicillin and trimethoprim/sulfamethoxazole for the treatment of thalassaemia (ontario.ca, Updated 2023-07-13 ↗)
Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗)
The Special Drugs Program will cover costs for the above drugs if the patient:
is an Ontario resident
has a valid Ontario Health Insurance (OHIP)
has one of the diseases or conditions covered
meets the established clinical criteria
is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sulfatrim-DS · DIN 00445282
Manufacturer: A A Pharma Inc.; listing date 1996-10-01
Daily cost (source): $0.4148
Health Canada: Marketed since 2019-04-10 · brand SULFATRIM DS · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Tablet · route Oral · ingredients TRIMETHOPRIM 160 MG, SULFAMETHOXAZOLE 800 MG · company Aa pharma inc · schedule Prescription
Sulfatrim-DS: Formulary list price $0.2074/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2074 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3679 · Verify on the e-Formulary ↗ (DIN 00445282)
Source record
DIN 00445282: Sulfatrim-DS
Raw flags: sec3=Y
Item: 084000003; group id 139; item number 0234; lccId None; manufacturer id AAP
Source form: Tab; strength: 800mg & 160mg
Recorded listing: General benefit
Source prices (unrounded): $0.2074; ministry $0.2074
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00445282
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3679Interchangeable products
Bactrim-DS · DIN 00371823 · not recorded
Septra DS · DIN 00368040 · not recorded
Shortage status: resolved shortage (ended 2025-04-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00445282
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Special Drugs ProgramSpecial Drugs Program: Amoxicillin, ascorbic acid (Vitamin C), deferoxamine, folic acid, hydrocortisone injection, penicillin and trimethoprim/sulfamethoxazole for the treatment of thalassaemia (ontario.ca, Updated 2023-07-13 ↗)
Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗)
The Special Drugs Program will cover costs for the above drugs if the patient:
is an Ontario resident
has a valid Ontario Health Insurance (OHIP)
has one of the diseases or conditions covered
meets the established clinical criteria
is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Trimel · DIN 00726540
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Daily cost (source): $1.0260
Health Canada: Dormant since 2021-05-14 · brand TEVA-TRIMEL · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Suspension · route Oral · ingredients TRIMETHOPRIM 8 MG/ML, SULFAMETHOXAZOLE 40 MG/ML · company Teva canada limited · schedule Prescription
Teva-Trimel: Formulary list price $0.1026/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1026 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7313 · Verify on the e-Formulary ↗ (DIN 00726540)
Source record
DIN 00726540: Teva-Trimel
Raw flags: sec3=Y
Item: 084000002; group id 139; item number 0232; lccId None; manufacturer id TEV
Source form: O/L; strength: 40mg & 8mg/mL
Recorded listing: General benefit
Source prices (unrounded): $0.1026; ministry $0.1026
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00726540
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7313Interchangeable products
Bactrim Sugar Free · DIN 00272485 · not recorded
Septra · DIN 00270644 · not recorded
Shortage status: active shortage (reported 2017-02-01, last updated 2017-10-13) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00726540
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2021-05-14 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.Discontinued 2001-07-19 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.
Special Drugs ProgramSpecial Drugs Program: Amoxicillin, ascorbic acid (Vitamin C), deferoxamine, folic acid, hydrocortisone injection, penicillin and trimethoprim/sulfamethoxazole for the treatment of thalassaemia (ontario.ca, Updated 2023-07-13 ↗)
Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗)
The Special Drugs Program will cover costs for the above drugs if the patient:
is an Ontario resident
has a valid Ontario Health Insurance (OHIP)
has one of the diseases or conditions covered
meets the established clinical criteria
is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Bactrim Sugar Free · DIN 00272485
Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01
Daily cost (source): $1.0260
Health Canada: Cancelled post market since 2001-07-19 · brand BACTRIM ROCHE SUSPENSION PAEDIATRIC · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Suspension · route Oral · ingredients SULFAMETHOXAZOLE 200 MG/5ML, TRIMETHOPRIM 40 MG/5ML · company Hoffmann-la roche limited · schedule Prescription
Bactrim Sugar Free: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1721 · Verify on the e-Formulary ↗ (DIN 00272485)
Source record
DIN 00272485: Bactrim Sugar Free
Raw flags: notABenefit=Y, sec3=Y
Item: 084000002; group id 139; item number 0232; lccId None; manufacturer id HLR
Source form: O/L; strength: 40mg & 8mg/mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00272485
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1721Interchangeable products
Septra · DIN 00270644 · not recorded
Teva-Trimel · DIN 00726540 · $0.1026
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00272485
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-10-07 — choose a marketed DIN from the same-category list.Discontinued 2025-10-07 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-10-07 — choose a marketed DIN from the same-category list.
Special Drugs ProgramSpecial Drugs Program: Amoxicillin, ascorbic acid (Vitamin C), deferoxamine, folic acid, hydrocortisone injection, penicillin and trimethoprim/sulfamethoxazole for the treatment of thalassaemia (ontario.ca, Updated 2023-07-13 ↗)
Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗)
The Special Drugs Program will cover costs for the above drugs if the patient:
is an Ontario resident
has a valid Ontario Health Insurance (OHIP)
has one of the diseases or conditions covered
meets the established clinical criteria
is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-10-07 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Septra · DIN 00270644
Manufacturer: Burroughs Wellcome Inc.; listing date 1996-10-01
Daily cost (source): $1.0260
Health Canada: Cancelled post market since 2025-10-07 · brand SEPTRA PEDIATRIC SUSPENSION · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Suspension · route Oral · ingredients SULFAMETHOXAZOLE 40 MG/ML, TRIMETHOPRIM 8 MG/ML · company Aspen pharmacare canada inc. · schedule Prescription
Septra: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1705 · Verify on the e-Formulary ↗ (DIN 00270644)
Source record
DIN 00270644: Septra
Raw flags: notABenefit=Y, sec3=Y
Item: 084000002; group id 139; item number 0232; lccId None; manufacturer id BWE
Source form: O/L; strength: 40mg & 8mg/mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00270644
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1705Interchangeable products
Bactrim Sugar Free · DIN 00272485 · not recorded
Teva-Trimel · DIN 00726540 · $0.1026
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00270644
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-10-07 — choose a marketed DIN from the same-category list.
Bactrim · DIN 00272469 · 400mg & 80mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-07-27 — choose a marketed DIN from the same-category list.Discontinued 2000-07-27 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-07-27 — choose a marketed DIN from the same-category list.
Special Drugs ProgramSpecial Drugs Program: Amoxicillin, ascorbic acid (Vitamin C), deferoxamine, folic acid, hydrocortisone injection, penicillin and trimethoprim/sulfamethoxazole for the treatment of thalassaemia (ontario.ca, Updated 2023-07-13 ↗)
Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗)
The Special Drugs Program will cover costs for the above drugs if the patient:
is an Ontario resident
has a valid Ontario Health Insurance (OHIP)
has one of the diseases or conditions covered
meets the established clinical criteria
is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-07-27 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Bactrim · DIN 00272469
Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01
Daily cost (source): $0.8736
Health Canada: Cancelled post market since 2000-07-27 · brand BACTRIM ROCHE TAB · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Tablet · route Oral · ingredients SULFAMETHOXAZOLE 400 MG, TRIMETHOPRIM 80 MG · company Hoffmann-la roche limited · schedule Prescription
Bactrim: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1804 · Verify on the e-Formulary ↗ (DIN 00272469)
Source record
DIN 00272469: Bactrim
Raw flags: notABenefit=Y, sec3=Y
Item: 084000001; group id 139; item number 0233; lccId None; manufacturer id HLR
Source form: Tab; strength: 400mg & 80mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00272469
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1804Interchangeable products
Septra · DIN 00270636 · not recorded
Sulfatrim · DIN 00445274 · $0.2184
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00272469
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2000-07-27 — choose a marketed DIN from the same-category list.
Septra · DIN 00270636 · 400mg & 80mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-07-31 — choose a marketed DIN from the same-category list.Discontinued 2003-07-31 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-07-31 — choose a marketed DIN from the same-category list.
Special Drugs ProgramSpecial Drugs Program: Amoxicillin, ascorbic acid (Vitamin C), deferoxamine, folic acid, hydrocortisone injection, penicillin and trimethoprim/sulfamethoxazole for the treatment of thalassaemia (ontario.ca, Updated 2023-07-13 ↗)
Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗)
The Special Drugs Program will cover costs for the above drugs if the patient:
is an Ontario resident
has a valid Ontario Health Insurance (OHIP)
has one of the diseases or conditions covered
meets the established clinical criteria
is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-07-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Septra · DIN 00270636
Manufacturer: Burroughs Wellcome Inc.; listing date 1996-10-01
Daily cost (source): $0.8736
Health Canada: Cancelled post market since 2003-07-31 · brand SEPTRA · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Tablet · route Oral · ingredients TRIMETHOPRIM 80 MG, SULFAMETHOXAZOLE 400 MG · company Glaxosmithkline inc · schedule Prescription
Septra: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1704 · Verify on the e-Formulary ↗ (DIN 00270636)
Source record
DIN 00270636: Septra
Raw flags: notABenefit=Y, sec3=Y
Item: 084000001; group id 139; item number 0233; lccId None; manufacturer id BWE
Source form: Tab; strength: 400mg & 80mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00270636
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1704Interchangeable products
Bactrim · DIN 00272469 · not recorded
Sulfatrim · DIN 00445274 · $0.2184
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00270636
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2003-07-31 — choose a marketed DIN from the same-category list.
Bactrim-DS · DIN 00371823 · 800mg & 160mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.Discontinued 2001-07-19 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.
Special Drugs ProgramSpecial Drugs Program: Amoxicillin, ascorbic acid (Vitamin C), deferoxamine, folic acid, hydrocortisone injection, penicillin and trimethoprim/sulfamethoxazole for the treatment of thalassaemia (ontario.ca, Updated 2023-07-13 ↗)
Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗)
The Special Drugs Program will cover costs for the above drugs if the patient:
is an Ontario resident
has a valid Ontario Health Insurance (OHIP)
has one of the diseases or conditions covered
meets the established clinical criteria
is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Bactrim-DS · DIN 00371823
Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01
Daily cost (source): $0.4148
Health Canada: Cancelled post market since 2001-07-19 · brand BACTRIM DS ROCHE TAB · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Tablet · route Oral · ingredients TRIMETHOPRIM 160 MG, SULFAMETHOXAZOLE 800 MG · company Hoffmann-la roche limited · schedule Prescription
Bactrim-DS: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2559 · Verify on the e-Formulary ↗ (DIN 00371823)
Source record
DIN 00371823: Bactrim-DS
Raw flags: notABenefit=Y, sec3=Y
Item: 084000003; group id 139; item number 0234; lccId None; manufacturer id HLR
Source form: Tab; strength: 800mg & 160mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00371823
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2559Interchangeable products
Septra DS · DIN 00368040 · not recorded
Sulfatrim-DS · DIN 00445282 · $0.2074
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00371823
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.
Septra DS · DIN 00368040 · 800mg & 160mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-07-31 — choose a marketed DIN from the same-category list.Discontinued 2003-07-31 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2003-07-31 — choose a marketed DIN from the same-category list.
Special Drugs ProgramSpecial Drugs Program: Amoxicillin, ascorbic acid (Vitamin C), deferoxamine, folic acid, hydrocortisone injection, penicillin and trimethoprim/sulfamethoxazole for the treatment of thalassaemia (ontario.ca, Updated 2023-07-13 ↗)
Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗)
The Special Drugs Program will cover costs for the above drugs if the patient:
is an Ontario resident
has a valid Ontario Health Insurance (OHIP)
has one of the diseases or conditions covered
meets the established clinical criteria
is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-07-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Septra DS · DIN 00368040
Manufacturer: Burroughs Wellcome Inc.; listing date 1996-10-01
Daily cost (source): $0.4148
Health Canada: Cancelled post market since 2003-07-31 · brand SEPTRA DS TABLETS · ATC J01EE01 SULFAMETHOXAZOLE AND TRIMETHOPRIM · form Tablet · route Oral · ingredients TRIMETHOPRIM 160 MG, SULFAMETHOXAZOLE 800 MG · company Glaxosmithkline inc · schedule Prescription
Septra DS: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2521 · Verify on the e-Formulary ↗ (DIN 00368040)
Source record
DIN 00368040: Septra DS
Raw flags: notABenefit=Y, sec3=Y
Item: 084000003; group id 139; item number 0234; lccId None; manufacturer id BWE
Source form: Tab; strength: 800mg & 160mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00368040
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2521Interchangeable products
Bactrim-DS · DIN 00371823 · not recorded
Sulfatrim-DS · DIN 00445282 · $0.2074
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00368040
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2003-07-31 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Some products covered without a code (check the product listing): CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN HYDROCHLORIDE, NORFLOXACIN
08:40 Miscellaneous Anti-Infectives
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
CEFADROXIL · Listed, not a benefit (1), General benefit (3)
• Acute uncomplicated urinary tract infections when caused by E.coli, Klebsiella species and
some strains of Proteus mirabilis.
PM: https://pdf.hres.ca/dpd_pm/00056563.PDF; date May 20, 2020; DIN 02235134; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE
For the treatment of acute, uncomplicated urinary tract infections due to susceptible strains of
Escherichia coli and Klebsiella pneumoniae. Limited clinical experience suggests the probability
of therapeutic response in infections due to susceptible strains of Proteus mirabilis and
Enterobacter species.
Cultures and susceptibility tests should be performed to determine the susceptibility of the
bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests.
For infections associated with urinary tract complications such as obstruction, or where tissue
involvement is suspected, the combination of trimethoprim/sulfamethoxazole has been shown to
be superior to trimethoprim alone.
https://pdf.hres.ca/dpd_pm/00025165.PDF
PM date: May 14, 2014
Source product: TRIMETHOPRIM TABLETS; DIN 02243116; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications
SULFATRIM (sulfamethoxazole and trimethoprim tablets) is indicated for treatment of
infections associated with the following gram-positive and gram-negative organisms:
Gram-Negative Organisms
Haemophilus influenzae
Neisseria gonorrhoeae
Escherichia coli
Klebsiella species
Enterobacter (Aerobacter) aerogenes
Proteus mirabilis
Proteus vulgaris
Salmonella species
Shigella species
Vibrio cholerae
Gram-Positive Organisms
Streptococcus pyogenes
Streptococcus viridans
Staphylococcus albus
Staphylococcus aureus
Diplococcus pneumoniae
Other Organisms
Brucella melitensis
Nocardia asteroides
Nocardia brasiliensis
Paracoccidioides brasiliensis
Pneumocystis jiroveci
Streptomyces somaliensis
Sensitivity tests should be performed wherever possible to determine choice of therapy. These
tests should be repeated if there is a failure to respond, relapse or early recurrence.
SULFATRIM may be indicated for the following infections when caused by susceptible strains of
the above organisms.
Urinary Tract Infections:
Treatment of acute uncomplicated urinary tract infections*. It is recommended that initial
episodes of uncomplicated urinary tract infections be treated with a single e…
https://pdf.hres.ca/dpd_pm/00085471.PDF
PM date: not printed or not captured
Source product: SULFATRIM; DIN 00445274; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Teva-Trimel · DIN 00726540
Shortage status: active shortage (reported 2017-02-01, last updated 2017-10-13) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00726540
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)
Other review policies
For Proloprim, Bactrim Sugar Free, Septra, Bactrim, Bactrim-DS, Septra DS: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.